Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Feature|Articles|June 14, 2024
- Pharmaceutical Executive: June 2024
- Volume 44
- Issue 6
Pharmaceutical Executive: June 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Beyond the Numbers: Extrapolating Today’s Trends Forwardover 2 years ago
Opposite Spectrumsover 2 years ago
2024 Pharm Exec Top 50 Companiesover 2 years ago
Craig Tooman: Silencing the Distractionsover 2 years ago
Regaining Trust in the Pharma Industryover 2 years ago
Succession Attack Plan: Get Strategic with Your Critical Rolesover 2 years ago
The Healthcare System is Changing—So How Should We Respond?over 2 years ago
Biotech Performance Remains Tethered to Rate Expectationsover 2 years ago
Pharm Exec Exclusive: Mark Cuban Talks Drug PricingAdvertisement
Related to this article
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
FDA Approves Tukysa Plus Trastuzumab and Pertuzumab as First-Line Maintenance Treatment for HER2-Positive Metastatic Breast Cancer
4
Before You Sign with a New Hub Vendor, Ask These Four Questions
5